Lori E. Shapiro

1.7k total citations
27 papers, 1.1k citations indexed

About

Lori E. Shapiro is a scholar working on Pharmacology, Pharmacology and Dermatology. According to data from OpenAlex, Lori E. Shapiro has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pharmacology, 7 papers in Pharmacology and 6 papers in Dermatology. Recurrent topics in Lori E. Shapiro's work include Drug-Induced Adverse Reactions (15 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Asthma and respiratory diseases (5 papers). Lori E. Shapiro is often cited by papers focused on Drug-Induced Adverse Reactions (15 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Asthma and respiratory diseases (5 papers). Lori E. Shapiro collaborates with scholars based in Canada, United Kingdom and United States. Lori E. Shapiro's co-authors include Neil H. Shear, Simon R. Knowles, Neil H. Shear, Raymond G. Schlienger, Manuela G. Neuman, P Poldre, Angela Mailis, Bethany Fitzsimmons, Peter Irwin and Elizabeth Weber and has published in prestigious journals such as Pain, Journal of the American Academy of Dermatology and Epilepsia.

In The Last Decade

Lori E. Shapiro

27 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lori E. Shapiro Canada 17 589 309 246 202 160 27 1.1k
Karim Aouam Tunisia 14 274 0.5× 67 0.2× 94 0.4× 76 0.4× 55 0.3× 100 728
Gillian Shepherd United States 14 751 1.3× 84 0.3× 63 0.3× 146 0.7× 45 0.3× 26 1.4k
Laura E. Rothuizen Switzerland 12 171 0.3× 28 0.1× 83 0.3× 53 0.3× 85 0.5× 38 733
Mao-Feng Sun Taiwan 22 174 0.3× 43 0.1× 45 0.2× 100 0.5× 60 0.4× 52 1.2k
Céline Villier France 13 99 0.2× 51 0.2× 53 0.2× 115 0.6× 60 0.4× 25 547
Paul Kotey United States 11 432 0.7× 108 0.3× 20 0.1× 88 0.4× 15 0.1× 17 813
Vincenzo Favilla Italy 25 92 0.2× 40 0.1× 216 0.9× 97 0.5× 118 0.7× 71 1.4k
Corine Ekhart Netherlands 14 89 0.2× 14 0.0× 31 0.1× 30 0.1× 87 0.5× 35 763
Francesca Marchegiani Italy 23 62 0.1× 28 0.1× 69 0.3× 300 1.5× 32 0.2× 46 1.4k
Alan K. Kamada United States 13 77 0.1× 23 0.1× 52 0.2× 37 0.2× 27 0.2× 29 883

Countries citing papers authored by Lori E. Shapiro

Since Specialization
Citations

This map shows the geographic impact of Lori E. Shapiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori E. Shapiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori E. Shapiro more than expected).

Fields of papers citing papers by Lori E. Shapiro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori E. Shapiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori E. Shapiro. The network helps show where Lori E. Shapiro may publish in the future.

Co-authorship network of co-authors of Lori E. Shapiro

This figure shows the co-authorship network connecting the top 25 collaborators of Lori E. Shapiro. A scholar is included among the top collaborators of Lori E. Shapiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori E. Shapiro. Lori E. Shapiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Neuman, Manuela G., Neil H. Shear, Izabella M. Malkiewicz, et al.. (2007). Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Translational research. 149(5). 243–253. 21 indexed citations
2.
Shapiro, Lori E., Simon R. Knowles, Elizabeth Weber, Manuela G. Neuman, & Neil H. Shear. (2003). Safety of Celecoxib in Individuals Allergic to Sulfonamide. Drug Safety. 26(3). 187–195. 36 indexed citations
3.
Knowles, Simon R., Lori E. Shapiro, & Neil H. Shear. (2003). Reactive Metabolites and Adverse Drug Reactions: Clinical Considerations. Clinical Reviews in Allergy & Immunology. 24(3). 229–238. 29 indexed citations
4.
Shapiro, Lori E., Simon R. Knowles, & Neil H. Shear. (2003). Drug Interactions of Clinical Significance for the Dermatologist. American Journal of Clinical Dermatology. 4(9). 623–639. 9 indexed citations
5.
Shapiro, Lori E. & Neil H. Shear. (2002). Drug interactions: Proteins, pumps, and P-450s. Journal of the American Academy of Dermatology. 47(4). 467–488. 69 indexed citations
6.
Shear, Neil H., Simon R. Knowles, & Lori E. Shapiro. (2002). Should Celecoxib be Contraindicated in Patients Who Are Allergic to Sulfonamides?. Drug Safety. 25(4). 297–300. 1 indexed citations
7.
Knowles, Simon R., Lori E. Shapiro, & Neil H. Shear. (2001). Should Celecoxib Be Contraindicated in Patients Who Are Allergic to Sulfonamides?. Drug Safety. 24(4). 239–247. 87 indexed citations
8.
Knowles, Simon R., Lori E. Shapiro, & Neil H. Shear. (2000). Drug eruptions. Current Problems in Dermatology. 12(2). 58–62. 2 indexed citations
9.
Knowles, Simon R., Lori E. Shapiro, & Neil H. Shear. (1999). Anticonvulsant Hypersensitivity Syndrome. Drug Safety. 21(6). 489–501. 223 indexed citations
10.
Schlienger, Raymond G., Lori E. Shapiro, & Neil H. Shear. (1998). Lamotrighe‐Induced Severe Cutaneous Adverse Reactions. Epilepsia. 39(s7). S22–6. 73 indexed citations
11.
Schlienger, Raymond G., Lori E. Shapiro, & Neil H. Shear. (1998). LAMOTRIGINEINDUCED SEVERE CUTANEOUS ADVERSE REACTIONS. 39(7). 14 indexed citations
12.
Mailis, Angela, et al.. (1997). Drug interactions in human neuropathic pain pharmacotherapy. Pain. 73(1). 3–13. 33 indexed citations
13.
Shapiro, Lori E., et al.. (1997). Cytochrome P-450 3A: Interactions with dermatologic therapies. Journal of the American Academy of Dermatology. 37(5). 765–771. 40 indexed citations
14.
Knowles, Simon R., Lori E. Shapiro, & Neil H. Shear. (1997). Serious dermatologic reactions in children. Current Opinion in Pediatrics. 9(4). 388–395. 19 indexed citations
15.
Shapiro, Lori E.. (1997). Comparative Safety of Tetracycline, Minocycline, and Doxycycline. Archives of Dermatology. 133(10). 1224–1224. 158 indexed citations
16.
Knowles, Simon R., Lori E. Shapiro, & Neil H. Shear. (1996). Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature.. PubMed. 132(8). 934–9. 129 indexed citations
17.
Shear, Neil H., Simon R. Knowles, Lori E. Shapiro, & P Poldre. (1996). Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. Journal of the American Academy of Dermatology. 35(5). 819–822. 41 indexed citations
18.
Shapiro, Lori E. & Neil H. Shear. (1996). Mechanisms of drug reactions: The metabolic track. Seminars in Cutaneous Medicine and Surgery. 15(4). 217–227. 34 indexed citations
19.
Shapiro, Lori E., et al.. (1983). Diltiazem: a new calcium antagonist for the treatment of chronic stable angina.. PubMed. 76(4). 179–179. 1 indexed citations
20.
Fitzsimmons, Bethany, et al.. (1978). Clinical study of mianserin, imipramine and placebo in depression: blood level and MHPG correlations.. British Journal of Clinical Pharmacology. 5(S1). 35S–41S. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026